2008-07-16 13:23:00
LONDON, UNITED KINGDOM–(EMWNews – July 16, 2008) – Reportlinker.com announces that a new market research report related to the Medical devices industry is available in its catalogue.
Cytology and HPV Testing World Markets
http://www.reportlinker.com/p090975/Cytology-and-HPV-Testing-World-Markets.html
Cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal cells. If the spread is not controlled, it can result in death. Cancer is caused by both external (chemicals, radiation and viruses) and internal (hormones, immune conditions and inherited mutations) factors. Causal factors may act together or in sequence to initiate or promote carcinogenesis. Ten or more years often pass between exposures or mutations and detectable cancer. Cancer is treated by surgery, radiation, chemotherapy, hormones and immunotherapy. The purpose of this TriMark Publications report is to describe the specific segment of the diagnostic market aimed at analysis cytology (the examination of cells using optical microscopy methods) specimens derived from the human female reproductive tract. It examines the measurement devices and their reagents and supplies used in hospitals, clinics, commercial laboratories and research institutions to detect cells and proteins for the diagnosis and monitoring of disease. The study describes the analytical methods used to separate, isolate, characterize and quantitate cells, DNA and proteins complex in biological systems related to the diagnosis and treatment of disease of the female reproductive tract, such as the cervix and vagina. The emphasis is on those companies and products that are actively developing and marketing laboratory instrumentation, reagents and supplies for performing cytology and related molecular diagnostic tests, such as human papillomavirus (HPV) and other inflammatory and sexually-transmitted diseases.
1. Overview 1.1 Statement of Report 1.2 About this Report 1.3 Scope of the Report 1.4 Objectives 1.5 Methodology 2. Introduction to Cancer Biology and the Diagnostic Industry 2.1 Cancer 2.1.1The Disease 2.1.2 Metastasis 2.1.3 Demographics and Statistics of Cancer 2.2 The Drivers of the Biotech and Diagnostics Industry 2.2.1 Technological Innovation 2.2.2 Government Funding 2.2.3 Pharmaceutical Development 2.3 Outlook for Tumor Markers 2.4 The Cancer Market 3. Cervical Cytology Testing Overview 3.1 Sector Background 3.2 Market Opportunity 3.3 Cervical Cancer 3.3.1 Screening for Cervical Cancer 3.3.2 Screening Procedures and Pap Smear Technology 4. Human Papillomavirus (HPV) Testing Overview 4.1 Market Overview 4.1.1 Human Papillomavirus 4.1.2 North American Market 4.1.3 European Market 4.1.4 Latin American Market 4.2 Hybrid Capture 2 HPV 4.3 Histology Market Overview 5. Cytology Market Structure 5.1 Key Players 5.1.1 TriPath Imaging 5.1.2 Cytyc 5.1.3 Molecular Diagnostics, Inc. 5.2 TriPath Products 5.2.1. Cervical Cytology Product Line 5.2.1.1 The SurePath Test Pack 5.2.1.2 PrepStain Slide Processor 5.2.1.3 FocalPoint Imaging System 5.2.1.4 SlideWizard Product Line 5.2.1.5 Molecular Diagnostics Products 5.2.1.6 Molecular Imaging Systems 5.2.1.7 Blood-based Reagents 5.2.2 Cytyc's Products 5.2.2.1 The ThinPrep System 5.2.2.1.1 Additional Applications of the ThinPrep System 5.2.2.2 The ThinPrep Process 5.2.2.3 Clinical Studies Evaluating the ThinPrep Pap Test 5.2.2.4 Competition 5.2.2.5 Surgical Products 5.2.2.6 The NovaSure System 5.2.2.7 Competition 5.2.3 Molecular Diagnostics' Products and Services 5.2.3.1 InPath System Key 5.3 Marketing and Sales Strategies 5.3.1 TriPath Imaging Sales and Marketing 5.3.1.1 Total Sales and Marketing 5.3.1.2 Commercial Operations 5.3.1.3 TriPath Oncology Sales and Marketing 5.3.1.4 Marketing Strategy 5.3.1.5 TriPath's Molecular Diagnostic Products 5.3.2 Cytyc Marketing and Sales 5.3.2.1 Sales and Marketing Costs 5.3.2.2 Cytyc's Marketing and Sales Strategy 5.3.2.2.1 Domestic Strategy 5.3.2.2.2 International Strategy 5.3.2.3 Sales Strategy - Cervical Cytology Product Line 5.3.2.3.1 Molecular Diagnostics 5.3.2.3.2 Marketing and Sales Organizations 5.3.2.3.3 Outside the U.S. with the Exception of Canada 5.4 Manufacturing TriPath, SurePath and PrepStain 5.4.1 Manufacturing Standards for Diagnostic Products 5.5 Competition 5.5.1 Molecular Diagnostic Reagents 6. Human Papillomavirus (HPV) Testing Market Structure 6.1 Key Players 6.1.1 Digene 6.1.1.1 Digene Products 6.1.2 Ventana Medical Systems 6.2 Products 6.2.1 HPV Tests 6.2.2 Chlamydia and Gonorrhea Tests 6.2.3 Blood Virus Tests 6.2.4 Instrumentation and Accessory Products 6.3 Sales and Marketing 6.3.1 International Markets 6.3.2 Europe 6.3.3 Central and South America 6.3.4 Asia/Pacific 6.3.5 Strategy 6.4 Manufacturing 6.5 Competition 6.5.1 Ventana 6.6 Ventana Staining Products 6.6.1 Ventana Products 7. Business Trends in the Industry 7.1 Industry Consolidation 7.2 Breath of Product Offering and Pricing 7.3 Government Regulation of Medical Devices 7.4 Strategic Business and Marketing Considerations 7.5 Commercial Opportunities in Cancer Markers 7.6 Moderators of Growth 7.7 Biotechnology Industry Trends 7.8 Pharmaceutical Industry Trends 7.9 Acquisition, License Agreement and Partnerships 7.10 Legal Developments 7.11 Sales and Marketing Strategies for Tumor Marker Tests 7.11.1 North American Market 8. Government Regulation 8.1 Government Regulation 8.2 U.S. FDA Approval 8.2.1 Clinical Laboratory Improvement Act of 1988 and State Laboratory Laws 8.2.2 Foreign Regulatory Approval 9. Legal Developments 9.1 Cytyc Legal Proceedings 9.2 Ventana Legal Proceedings 10. Third-Party Reimbursement 10.1 Limited Reimbursements by Third-party Payers Obstruct Sales 10.2 Cytyc ThinPrep 10.3 CPT Codes and HCPCS Codes 10.4 Professional Component Fee 10.5 Regional Payer Relations Managers 10.6 Reimbursement Codes Classification 10.6.1 Reporting Screening and Diagnostic Pap Smears 10.6.2 HCPCS (HCFA Common Procedure Coding System) Code Definitions 10.6.3 CPT (Current Procedural Terminology) Code Definitions 10.7 A Note on Statutory Limitations 10.8 Cervical Cytology Product Line 10.9 Molecular Diagnostic Products and Imaging Systems 11. Barriers in Business 11.1 Barriers in the Business Section 11.1.1 Cytyc Barriers 11.1.2 Digene Risk Factors 11.1.3 Ventana 11.1.3.1 Ventana factors that could affect future results 12. Acquisition Activity 12.1 Acquisition 12.2 Cytyc Acquisition Activity & Acquisition of Novacept 13. Research & Development Activity 13.1 Cytyc In-Process R&D and Developed Technology 13.2 TriPath Research & Development 13.2.1 Development of Molecular Diagnostic Products 13.3 Digene Research & Development 13.4 Ventana Research & Development 13.4.1 Instrumentation Development Projects 13.4.2 Reagent Development Projects 14. Intellectual Property 14.1 TriPath Proprietary Technology and Intellectual Property 14.2 Digene Intellectual Property 14.2.1 Hybrid Capture Technology 14.2.2 Rights to HPV Types 14.2.3 Other Intellectual Property 14.2.3.1 Trademark 14.3 Ventana Patents and Proprietary Rights 15. Cytyc Profile 15.1 Company Information 15.1.1 Contact 15.1.2 About the Cytyc Corporation 15.2 Products/Business Segments 15.2.1 Diagnostic Products 15.2.2 The ThinPrep Process 15.3 Management 15.3.1 Top Executives and Salaries 15.3.2 Board of Directors 16. Analytical Section 16.1 Financial Analysis 16.2 Company's Strategies 16.3 SWOT Analysis 17. Industry/Market Landscape 17.1 Industry Overview 17.1.1 Industry Key Players 17.1.1.1 Cytology Screening Testing Market Structure 17.1.1.2 Human papillomavirus (HPV) Testing Market Structure 17.2 Outlook on the Industry 17.3 Trends, Issues, Challenges and Opportunities: An Analysis 17.4 Molecular Diagnostics Products 17.4.1 Microscopic Slide Based Reagents 17.4.2 Molecular Imaging Systems 17.4.3 Blood-Based Reagents 17.5 Competitive Landscape 17.6 Products/Business Segments 17.6.1 Digene's HPV Tests 17.6.2 Digene's Chlamydia and Gonorrhea Tests 17.6.3 Digene's Blood Virus Tests 17.6.4 Digene's Instrumentation and Accessory Products 18. Digene Management 18.1 Board of Directors 18.2 Top Executives and Salaries 18.3 Analytical Section 18.3.1 Financial Analysis 18.4 Company's Strategies 18.5 SWOT Analysis 19. Industry/Market Landscape 19.1 Digene Industry Overview 19.1.1 Industry Definition 19.1.1.1 Cytology Products 19.1.2 Industry Key Players 19.1.3 Company's Outlook on the Industry 19.2 Trends, Issues, Challenges and Opportunities - An Analysis 19.3 Competitive Landscape 19.4 Competition 19.4.1 Digene's Competitive Advantage 19.4.2 Molecular Diagnostic Reagents 19.4.3 TriPath Imaging, Inc. 19.5 Products/Business Segments 19.5.1 Cervical Cytology Product Line (Formerly the i3 Series Product Line) 19.5.1.1 PrepStain Slide Processor 19.5.1.2 FocalPoint Imaging System 19.5.1.3 SlideWizard Product Line 19.5.2 Molecular Diagnostics Products 19.5.2.1 Microscopic Slide Based Reagents 19.5.2.2 Molecular Imaging Systems 19.5.2.3 Blood-Based Reagents 19.6 Management 19.6.1 Top Executives and Salaries 20. Analytical Section 20.1 Financial Analysis 20.1.2 TriPath Oncology Revenues 20.2 Company's Strategies 20.3 SWOT Analysis 21. Industry/Market Landscape 21.1 Industry Overview 21.1.1 Industry Definition 21.1.1.1 Cytology Products 21.1.1.2 Molecular Diagnostic Products 21.1.2 Industry Key Players 21.2 Company's Outlook on the Industry 21.3 Trends, Issues, Challenges and Opportunities: An Analysis 21.4 Molecular Diagnostics Products 21.4.1 Blood-Based Reagents 21.5 Competitive Landscape 21.5.1 Competition 21.5.1.2 TriPath's Competitive Advantage 21.5.1.3 Molecular Diagnostic Reagents 21.5.1.4 Ventana Appendix 1: Breast Cancer Appendix 2: Ovarian Cancer Appendix 3: Malignant Melanoma INDEX OF TABLES Table 2.1: Drug Development by Type of Cancer Table 2.2: The 402 Organ Specific Medicines in Development for Cancer Table 2.3: Leading Sites of Cancer Cases and Deaths in the U.S. by Sex Table 2.4: Number of Cancer Cases and Deaths by Type of Cancer Table 2.5: Cancer Cases and Deaths by Region Table 2.6: Cancer Death Rates per 100,000 Population (and Rank) for All Cancer Sites by Country Table 2.7: Cancer-Associated Genes Table 2.8: Carcinogens in the Workplace Table 2.9: Private Funding Levels for the Biotechnology Segment, 1995 to 2005 Table 2.10: Top Ten Biotech Corporations Table 2.11: Global Pharmaceutical Industry R&D Spending, 1980 to 2004 Table 2.12: U.S. Government NIH Research Budget, 1995 to 2004 Table 2.13: Herceptin Worldwide Sales, 1999 to 2005 Table 2.14: Classes of Drugs Used to Treat Breast Cancer Table 2.15: Women's Cancers in the U.S., 2005 Table 2.16: Five-Year Disease - Free Survival by Stage at Diagnosis Table 3.1: Number of Pap Smears Performed by Country Table 4.1: Digene Product Revenues and Assets Table 5.1: TriPath Product Sales Share Overview Table 5.2: Cytyc Product Overview Table 5.3: Pap Tests in Top European Markets Table 5.4: Pap Tests in Top Asian Markets Table 5.5: Cytyc Annual Sales Table 5.6: Cytyc Annual Net Income Table 6.1: HPV Market Size, 2003 to 2011 Table 6.2: Product, Infection and Market Table 6.3: Instrumentation and Accessories, Infection and Market Table 7.1: List and Discounted Pricing for Abbott Tumor Marker Tests Table 10.1: CPT and HCPCS Codes Table 10.2: National Limitation Amounts Table 10.3: NLAs for Various CPT Codes Table 14.1: HPV Types Status and Patents Table 16.1: Percentage of Cytyc's Net Sales Table 17.1: Market Share of Cytology Products Table 17.2: Diagnostic Test Kit Products and Markets
To order this report:
Cytology and HPV Testing World Markets
http://www.reportlinker.com/p090975/Cytology-and-HPV-Testing-World-Markets.html
|
For more information, please contact Reportlinker.com Nicolas (718) 887-3024 Email: [email protected] |
|
Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89
Get Unlimited Organic Website Traffic to your Website
TheNFG.com now offers Organic Lead Generation & Traffic Solutions
